Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


Aventis: Geared for the patent regime

Jun 17, 2005

With the advent of the patent regime in India, MNC pharma companies stand to gain a lot in terms of new product launches and consequently increased revenues. Being an MNC, Aventis is all set to exploit this opportunity. In this article, we take a look at how the company has performed over the years and what lies ahead.

Aventis: Looking healthier

Oct 23, 2004

MNC pharma major Aventis, recently announced its 3QCY04 and 9mCY04 results. During 3QCY04, the topline grew by 13.1% YoY while the bottomline grew by 63% YoY. For the first nine months of the year, while the topline growth was 11.2%, the bottomline grew by an even more impressive 73.7% as compared to same period last year. Cost cutting measures has seen the company improving its operating margins by an astonishing 1120 basis points during the third quarter.

Aventis Pharma 2QFY05 net up 63% YoY

Oct 21, 2004

MNC pharma major Aventis, declared its 3QCY04 and 9mCY04 results. In 3QCY04, the topline grew by 13.1% while the bottomline grew by 63%. For the first nine months of the year the topline growth was 11.2% and the bottomline grew by 73.7%. The operating margins o the company has expanded by almost 11% owing to the cost cutting drive.

Performance Summary: Pharma sector

Aug 11, 2004

Pharma sector is generally believed to be a defensive sector, as factors that impact demand and supply for this sector are to an extent, different from factors that impact economic growth. This is not to say that the sector is not impacted by economic performance at all. This, to some extent, is true and is apparent from the graph below. While the BSE Sensex has declined by 9% since April 2004, the pharma index is down only 4% in the same period.

Aventis Pharma: Impressive performance

Mar 19, 2004

Aventis Pharma has reported 5.8% YoY growth in topline during year ended December 2003. The bottomline growth was much faster at 61% YoY. Aventis clocked a 9.6% topline and a significant 81% bottomline growth during the quarter ended December. Let’s take a detailed look at the financial performance of the company.

Aventis Pharma: Strategy paying off

Oct 21, 2003

Aventis Pharma announced its 3QFY04 results last week. While the company has reported a marginal 2% growth in the topline, operating efficiencies have helped it record a sharp 57% rise in bottomline. For 9mFY04 also, the company has reported a 6% and 54% growth in net sales and net profit respectively. In this context, let us take a brief look at the company’s performance.

Aventis Pharma: Going strong

Aug 8, 2003

MNC pharma major, Aventis Pharma (formerly Hoechst Marion) has announced its June quarter results recently. The company recorded a 9% increase in the topline and a strong 37% growth in the bottomline. For the first half of FY04 (1HFY04) Aventis registered a 7% increase in revenues and net profits surged by 52%. In this context, let us briefly evaluate the performance of the company.

Aventis: MNC with a difference

Jul 3, 2003

MNC pharma companies have over the years steadily lost market share to their domestic counterparts. From a market share (in value terms) of almost 90% in the 70s, MNC pharma companies now barely account for 20% of domestic pharma sales. Absences of product patents and a consequent reluctance in launching new products coupled with rigid price controls have been limiting growth prospects. However, Aventis Pharma (APL) has adopted a strategy to beat this trend. APL has an aggressive product introdu

Aventis - VAT clouds growth

Apr 29, 2003

Aventis Pharma, one of the major MNC players in the country, has posted an impressive performance for the first quarter ended March 2003. After restructuring its operations (includes exiting from non-profitable brands) that led to a fall in net profit in FY03, there is an overall improvement in revenue and margin expansion.

Aventis Pharma: Strategic focus

Mar 20, 2003

Aventis Pharma Limited, one of the leading pharmaceutical companies in India, recently announced FY03 results. We take a detailed look at the company's performance.

Aventis Pharma: OPM disappointment continues…

Oct 31, 2002

Aventis Pharma, has reported nearly 13% topline growth for 3QFY03 on the back of strong performance of its strategic brands and jump in exports to CIS countries. The results for the relevant period under review are on a merged basis with RPR (Rhone Poulenc Rorer) and hence not exactly comparable on a like to like basis with the previous year numbers.

Aventis Pharma: Margins slide

Jul 31, 2002

Aventis Pharma, has reported a strong topline growth for 1HFY03 on the back of strong performance of its strategic brands and jump in exports to CIS countries. The results for the relevant period under review are on a merged basis with RPR (Rhone Poulenc Rorer) and hence not exactly comparable on a like to like basis.

Aventis Pharma: Sales jumps, margins dip

Apr 18, 2002

The results declared by Aventis pharma generate mixed reactions. While sales growth for the company has been better than expected, a fairly sharp drop in margins is discouraging. The company has recorded a sales growth of 14% from Rs 1.3 bn to Rs 1.5 bn in the first quarter of current year (FY03). However, the results for FY03 are on a merged basis with Rhone Poulenc Rorer (RPR) and hence not exactly comparable.

Aventis Pharma: Encouraging performance

Mar 20, 2002

The restructuring exercise at Aventis is finally through and the results of the same are partially evident in FY02 results. Aventis has reported steady rise in operating margins during all the quarters of last year. The key brands of the company have logged attractive growth numbers inspite of stiff competition and the new product pipeline ahead seems to be exciting.

Aventis Pharma: Are valuations attractive?

Feb 20, 2002

Aventis Pharma (erstwhile Hoechst Marion) seems to be taking the right steps to inculcate much wanted growth in the company. While operating margins are on a steady rise, product portfolio of the company is increasingly becoming enviable. The company is slowly and steadily shifting its focus towards high margin specialised therapeutic segments. The DPCO order unfortunately seems to be acting as a dampener for the company's valuations.

Hoechst Marion: PBT up 28%

Oct 20, 2001

Aventis Pharma (formerly Hoechst Marion Roussel) has posted a PBT of Rs 255 m, a rise of 28% for 3QFY02. Sales grew by around 8% fuelled by a strong growth in export business.

Hoechst: Is restructuring paying?

Sep 3, 2001

Hoechst Marion Roussel (HMR) went through a major restructuring exercise in the last three years. The company aggressively rationalized its product portfolio replacing older products and reducing its DPCO exposure. The DPCO exposure of the company, which was around 60% a couple of years back, is now down to 40%. Quick launch of new products helped in increasing new product contribution to the total domestic formulations sales to 16% (up from 6% couple of years back). Post restructuring, the comp

Hoechst Marion: Operating margin Zooms

Jul 30, 2001

Hoechst Marion Roussel Ltd (HMR) has posted a PBT of Rs 215 m, a rise of 47% inspite of 7% reduction in turnover. This rise was on the back of an 810 basis points improvement in operating profit margins of the company. The rise in operating margins was due to company's focus on strategic products, better efficiencies and reduction in operating expenses.

Hoechst: Hope for the best

Jun 27, 2001

The sales figures for the first five months of Hoechst (now Aventis Pharma Ltd) are bit disappointing. While the company had reported a growth of 10.8% in the first quarter (January to March) of the current year, the first five months have seen a sales growth of only 5%. This implies that sales have infact shown degrowth of over 2% in the months of April and May. The volatility in sales may be due to recent product restructuring carried out by the company.

Hoechst Marion : Profit Before Tax Zooms 69%

Apr 27, 2001

Hoechst Marion Roussel Ltd has posted a net profit of Rs 211m for the quarter ended March 31, 2001, as compared to Rs 132 m for the corresponding period last fiscal. Net sales increased by 10.8% to Rs 1,178 m in the quarter ended March 31, 2001.Profit Before Tax zoomed up 69.4%.

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms